Mixed chimerism after allogeneic hematopoietic stem cell transplantation for severe aplastic anemia. Issue 1 (1st January 2021)

• Record Type: Journal Article
• Authors: Zhang, Yuling; Li, Yumiao; Wu, Liangliang; Zhou, Ming; Wang, Caixia; Mo, Wenjian; Chen, Xiaowei; Xu, Shilin; Zhou, Ruiqing; Wang, Shunqing; Zhang, Yuping
• Is Part Of: Hematology. Volume 26:Issue 1(2021)
• Page Start: 435
• Page End: 443
• Publication Date: 2021-01-01
• Subjects: Severe aplastic anemia -- hematological stem cell transplantation -- mixed chimerism -- risk factor -- secondary graft failure; Blood -- Diseases -- Periodicals; Hematology -- Periodicals; Blood -- Transfusion -- Periodicals; 616.15005
• DOI: 10.1080/16078454.2021.1938422
• Languages: English
• ISSNs: 1024-5332

Abstract

ABSTRACT: Background: Mixed chimerism (MC) frequently occurs in patients with severe aplastic anemia (SAA) after allogeneic hematological stem cell transplantation (allo-HSCT). Methods : A retrospective study on 287 patients with SAA who underwent allo-HSCT between October 2012 and January 2020 was conducted to explore the outcomes, risk factors and treatment options for MC. Among 287 AA patients who excluded Fanconi anemia (FA), Congenital dyskeratosis (DKC), Paroxysmal nocturnal hemoglobinuria (PNH), etc.112 underwent matched sibling donor (MSD)-HSCT, 91 matched unrelated donor-HSCT and 84 haploidentical-HSCT. Patients were divided into the following 4 groups: group 1: Donor chimerism (DC); group 2: MC without cytopenia; group 3: MC with cytopenia; group 4: secondary graft failure (SGF). Results : Compared with the other three groups, SGF predicted a poor prognosis of SAA ( P < 0.001). In addition, SGF was associated with the early (within 3 months after transplantation) presence of MC and the high levels of MC. Uni- and multivariate logistic regression analysis showed that donor/recipient sex-mismatching and CTX + ATG regimen were high-risk factors for MC. Of note, in MC patients with cytopenia (group 3), the effective response rate reached 55% (6/11) following enhanced immunosuppression combined with cellular therapy, while only one of the four was effective who received enhanced immunosuppression alone. Conclusion : SGF was associated with poor prognosis, early presence of MC and increased levels of recipient chimerism. The donor/recipient sex-mismatching and CTX + ATG regimen based MSD-HSCT were risk factors for MC. Cellular therapy could improve the effective response rate of patients with progressive MC.